UK research services company Envigo has appointed Dr Adrian Hardy as its new president and chief executive officer, which will take effect from 1 July.
He will succeed Brian Cass in the role who becomes executive chairman, while the previous chairman Andrew Baker becomes chairman emeritus.
Dr Hardy first joined Envigo in 2002 in a business development role, before taking on a series of increasingly senior posts, most recently having served as chief operating officer at the firm.
Prior to joining Envigo, Dr Hardy was a product development manager for Novartis, and served as a director at law firm iPulse.
Dr Hardy said: “I'm delighted and extremely proud to be taking on this role at such an exciting time for Envigo and the research community.
“I've worked closely with Andrew and Brian during my time with the company and would like to thank them for their contributions to making Envigo the world class company it is today.
“Their vision and leadership has positioned our company as a market leader, and I look forward to continuing to work with them in their new roles as we strive to build on the growth and success of Envigo.”
No results were found
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...